Closely monitoring disease activity without starting medication immediately — an approach called watchful waiting — may raise the risk of relapse for people with mild IgG4-related disease (IgG4-RD), according to a real-world study from China. In people with IgG4-RD, watchful waiting is sometimes used as a strategy for patients…
Discussion
Although I live with a chronic illness, I’ve always tried to shape my life with as much freedom and independence as possible. This was true long before anyone put a name to my condition: IgG4‑RD. The ability to make my own choices and decide for myself how a day…
Regulatory authorities in Japan have granted orphan drug designation to rilzabrutinib, an oral therapy candidate for immunoglobulin G4-related disease (IgG4-RD) that’s now in late-stage clinical testing globally. In Japan, orphan drug designation is awarded to experimental medicines that aim to treat diseases affecting fewer than 50,000 people in the…
Get regular updates to your inbox.
